SynthesisThe oncologist2025
Incidence and risk of hypertension and proteinuria in cancer patients treated with lenvatinib: a systematic review and meta-analysis.
Synthesis in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiovascular Complications Associated with Uro-Oncology Treatments-A Primer for the Clinician.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPublished data regarding the overall risks and incidence of hypertension and proteinuria associated with lenvatinib remain unclear.
methodsWe performed a systematic review and meta-analysis to quantify the precise risks and incidence of lenvatinib-associated hypertension and proteinuria. We systematically searched PubMed, Cochrane Library, and Web of Science databases for studies on the incidence of hypertension and proteinuria, which were published until April 24, 2023.
resultsA total of 10 443 patients were included in the 64 studies identified from the literature. The incidence of all-grade and grade ≥3 hypertension was 50% (95% confidence interval [CI]: 43%-58%) and 14% (95% CI, 10%-18%) for patients treated with lenvatinib. The incidence of all-grade and grade ≥3 proteinuria was 32% (95% CI, 26%-38%) and 6% (95% CI, 4%-7%), respectively. Compared with controls, lenvatinib significantly increased the risk of all-grade hypertension (odds ratio [OR]: 2.4, 95% CI, 1.4-4.1), grade ≥3 hypertension (OR: 2.7, 95% CI, 1.2-6.0), all-grade proteinuria (OR: 3.5, 95% CI, 1.9-6.6), and grade ≥3 proteinuria (OR: 2.85, 95% CI, 1.5-5.3). Compared to low-dose lenvatinib (≤12 mg/day), high-dose lenvatinib (≥20 mg/day) treatment significantly increased the risks of all-grade hypertension (OR: 4.7, 95% CI, 4.2-5.2), grade ≥3 hypertension (OR: 7.7, 95% CI, 6.8-8.7), all-grade proteinuria (OR: 1.8, 95% CI, 1.6-2.0), and grade ≥3 proteinuria (OR: 1.7, 95% CI, 1.5-2.1).
conclusionOur review revealed that lenvatinib treatment increases the risks of hypertension and proteinuria, particularly with high-dose lenvatinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.